MetaVia Inc. — Director's Dealing 2016

Aug 5, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Gemphire Therapeutics Inc. (GEMP)
CIK: 0001638287
Period of Report: 2016-08-04

Reporting Person: Sooch Mina (Director, President, CEO & Treasurer, 10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	641232	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Option (right to buy)	$1.344	2025-06-28	Common Stock (5220)		Direct
Series A Convertible Preferred Stock	$		Common Stock (11078)		Indirect
8% Convertible Subordinated Promissory Notes	$6.7059		Common Stock ()		Indirect

Footnotes

F1: The Series A Convertible Preferred Stock has no expiration date, and shall convert into shares of common stock, par value $0.001 per share, of Gemphire Therapeutics Inc. (the "Company") on a one-for-one basis immediately prior to the closing of the Company's initial public offering.

F2: Arvinder Sooch is the reporting person's husband. These shares are indirectly owned by him as trustee of the Arvinder S. Sooch Trust.

F3: The notes were issued in the original principal amount of $175,000. The outstanding principal and accrued interest on such notes will automatically convert into shares of common stock, par value $0.001 per share, of the Company immediately prior to the closing of the Company's initial public offering. The notes bear interest at a rate of 8% per annum. The notes have accrued interest of $6,785 to date and will continue to accrue interest until conversion.